NewswireToday - /newswire/ -
Singapore, Singapore, 2007/05/21 - DN Venture Partners is organising the Asia Biotech Business Mission 2007, from 5th to 9th November 2007, with the aim to help companies and investors understand and capture opportunities in the biotech industry in Asia.
DN Venture Partners (DNVP) is organising the Asia Biotech Business Mission 2007, from 5th to 9th November 2007. This mission will take delegates to Singapore, Malaysia and Thailand, to visit biotech companies, research institutes and government agencies promoting the industry. It will conclude with the delegates’ participation at Bio-Asia 2007 in Bangkok, Thailand. The mission targets participants from the financial and biomedical sectors within Europe and the United States, and it aims to help companies and investors understand and capture opportunities in the biotech industry in Asia.
The 2007 Asia Biotech Business Mission follows on the success of the 2005 Asia Biotech Business Mission, in which participants from the European biotech and investment industry met with key industry players in Asia. Mission participant, Dr Oscar Izeboud commented that it was an “excellent mission, well organized, with high-level contacts at companies and government organizations.”
According to Mr Marvin Ng, Director (Asia) of DNVP, “The 2005 mission resulted in subsequent deals for some of the participants and we hope to replicate its success in the upcoming mission.”
DN Venture Partners is a Singapore and Germany based business consulting firm. DNVP provides essential business development support services to companies seeking to expand their business activities in Asia.
Background Information on Asia’s Biotech Industry
The biotech industry in Asia has grown substantially in the past few years. This growth is accompanied by significant opportunities in the biotech sector in countries like Singapore and Taiwan. These countries have committed significant resources and effort to build up their respective biotech industry and attract inward investments.
Last year, Singapore announced that it was setting aside more than US$8 billion to strengthen its R&D capabilities over the next few years. More recently, Malaysia became the third largest participant at BIO 2007 (after the United States and Canada) where its companies seek out collaborations with international biotech organisations. Other countries like Thailand and Korea are also actively developing their respective industry.
Although still in its early phase of development, the biotech industry in Asia has already achieved some early success. For example, Thailand’s efforts in agri-biotechnology have enabled the country to maintain its lead as a major agriculture player. Taiwan, on the other hand, boasts one of the largest numbers of home-grown biotech companies. All these countries are contributing to Asia’s rise as a major force in biotech and offer significant opportunities to companies and investors alike.